Evidence map›Paper›PMID 28271256›Full record

ArticleClinical and experimental nephrology2017

Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.

Takenori Niioka, Hideaki Kagaya, Mitsuru Saito, Takamitsu Inoue, Kazuyuki Numakura, Ryohei Yamamoto, Tomonori Habuchi, Shigeru Satoh, Masatomo Miura

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Takenori NiiokaDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan.
Hideaki KagayaDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan.
Mitsuru SaitoDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Takamitsu InoueDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Kazuyuki NumakuraDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Ryohei YamamotoDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Tomonori HabuchiDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Shigeru SatohCenter for Kidney Disease and Transplantation, Akita University Hospital, 1-1-1 Hondo, Akita, Japan.
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan. m-miura@hos.akita-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe investigated the impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations (C

methodsLogistic regression analysis was carried out to estimate the distinction rate of CYP3A5 genotypes based on the C

resultsRecipients with at least one CYP3A5*1 wild-type allele (EMs) and recipients with homozygous expression of the variant allele CYP3A5*3 (PMs) were significantly identified using the tacrolimus C

conclusionsThe tacrolimus C

Indexed as

Kidney TransplantationPharmacogenomic VariantsAsian PeopleCalcineurin InhibitorsChi-Square DistributionCytochrome P-450 CYP3ADrug CompoundingDrug Dosage CalculationsDrug MonitoringGenotypeGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsIncidenceJapanCalcineurin InhibitorsCYP3A5 protein, humanCytochrome P-450 CYP3AImmunosuppressive AgentsTacrolimusCYP3A5 genotypeDose-adjusted trough concentrationFormulationRejectionRenal transplantationTacrolimus

Identifiers

PMID28271256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.